Premier Biomedical Inc
Premier Biomedical, Inc., a research-based company, discovers and develops medical products for the treatment of PTSD, cancer, and various other diseases. It offers pain management products comprising pain relief patch of hemp oil extracts; water-based and oil-based roll-on applicators; oil-based pump spray applicators; and ointments through its Website painreliefmeds.com and various distributors… Read more
Premier Biomedical Inc (BIEI) - Total Liabilities
Latest total liabilities as of March 2025: $2.56 Million USD
Based on the latest financial reports, Premier Biomedical Inc (BIEI) has total liabilities worth $2.56 Million USD as of March 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Premier Biomedical Inc - Total Liabilities Trend (2010–2024)
This chart illustrates how Premier Biomedical Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Premier Biomedical Inc Competitors by Total Liabilities
The table below lists competitors of Premier Biomedical Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Windtree Therapeutics Inc
NASDAQ:WINT
|
USA | $27.58 Million |
|
Joshua Gold Resources Inc
PINK:JSHG
|
USA | $2.02 Million |
|
Sylla Gold Corp.
PINK:SYGCF
|
USA | $2.24 Million |
|
Cartica Acquisition Corp Warrant
NASDAQ:CITEW
|
USA | $11.07 Million |
|
Fbec Worldwide
PINK:FBEC
|
USA | $1.82 Million |
|
Colibri Resource Corporation
PINK:CRUCF
|
USA | $2.30 Million |
|
NuGene International Inc
PINK:NUGN
|
USA | $2.59 Million |
|
Cyon Exploration Ltd
PINK:CYNXF
|
USA | $1.61 Million |
Liability Composition Analysis (2010–2024)
This chart breaks down Premier Biomedical Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.00 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 721.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Premier Biomedical Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Premier Biomedical Inc (2010–2024)
The table below shows the annual total liabilities of Premier Biomedical Inc from 2010 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $2.58 Million | +3.80% |
| 2023-12-31 | $2.49 Million | +9.04% |
| 2022-12-31 | $2.28 Million | +1.37% |
| 2021-12-31 | $2.25 Million | +1.46% |
| 2020-12-31 | $2.22 Million | +14.79% |
| 2019-12-31 | $1.93 Million | -16.37% |
| 2018-12-31 | $2.31 Million | -18.00% |
| 2017-12-31 | $2.82 Million | +303.02% |
| 2016-12-31 | $699.67K | +47.68% |
| 2015-12-31 | $473.79K | +151.49% |
| 2014-12-31 | $188.39K | -31.37% |
| 2013-12-31 | $274.50K | +130.36% |
| 2012-12-31 | $119.16K | +3746.38% |
| 2011-12-31 | $3.10K | +27.54% |
| 2010-12-31 | $2.43K | -- |